DAX
17.932,17 -186,15 (-1,03%) Euro Stoxx 50
4.921,22 -59,87 (-1,20%) Dow Jones 30
37.939,90 +123,98 (+0,33%) Gold
2.314,30 +11,40 (+0,50%) EUR/USD
1,0679 +0,0007 (+0,06%) Bitcoin EUR
53.497,84 -3.054,62 (-5,40%)
Evotec AG (EVT.DE)
Evotec AG
Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com
Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 5.061
Beschreibung
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Corporate Governance
Evotec AGs ISS Governance QualityScore, Stand 29. April 2024, lautet 5. Die grundlegenden Scores sind Audit: 3, Vorstand: 2, Shareholderrechte: 1, Kompensation: 7.
